China Pharma Holdings (CPHI) Receivables - Other (2010 - 2026)
China Pharma Holdings (CPHI) posted Receivables - Other of $61657.0 for Q1 2026, up 25.16% on a QoQ basis from $49261.0 in Q4 2025, and up 57.91% year-over-year from $39046.0 in Q1 2025.
China Pharma Holdings (CPHI) Receivables - Other (2010 - 2026) Analysis & Trends
China Pharma Holdings' Receivables - Other history runs 16 years deep, the most recent figure standing at $61657.0 for Q1 2026.
- Quarterly Receivables - Other rose 57.91% year-over-year to $61657.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61657.0 (up 57.91% YoY) and the FY2025 annual result came in at $49261.0, up 62.65% from the prior year.
- Receivables - Other was $61657.0 for Q1 2026 at China Pharma Holdings, up from $49261.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $1.2 million in Q1 2022 and bottomed at $28660.0 in Q2 2024.
- A 5-year average of $270495.4 and a median of $48361.0 in 2025 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2022 — Receivables - Other sank 97.96% — and 2023, when it soared 442.04%.
- China Pharma Holdings' Receivables - Other stood at $29139.0 in 2022, then surged by 442.04% to $157944.0 in 2023, then sank by 80.82% to $30286.0 in 2024, then jumped by 62.65% to $49261.0 in 2025, then grew by 25.16% to $61657.0 in 2026.
- Business Quant data shows CPHI's Receivables - Other at $61657.0 in Q1 2026, $49261.0 in Q4 2025, and $61275.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61,657.00 |
| Mar 31, 2026 | 61,657.00 |
| Dec 31, 2025 | 49,261.00 |
| Dec 31, 2025 | 49,261.00 |
| Sep 30, 2025 | 61,275.00 |
| Sep 30, 2025 | 61,275.00 |
| Jun 30, 2025 | 48,361.00 |
| Jun 30, 2025 | 48,361.00 |
| Mar 31, 2025 | 39,046.00 |
| Mar 31, 2025 | 39,046.00 |
| Dec 31, 2024 | 30,286.00 |
| Dec 31, 2024 | 30,286.00 |
| Sep 30, 2024 | 46,553.00 |
| Sep 30, 2024 | 46,553.00 |
| Jun 30, 2024 | 28,660.00 |
| Jun 30, 2024 | 28,660.00 |
| Mar 31, 2024 | 32,220.00 |
| Mar 31, 2024 | 32,220.00 |
| Dec 31, 2023 | 157,944.00 |
| Dec 31, 2023 | 157,944.00 |